Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to $123.0 million.

  • Artiva Biotherapeutics' Cash & Equivalents rose 120.11% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.0 million, marking a year-over-year increase of 120.11%. This contributed to the annual value of $40.2 million for FY2024, which is 24.80% down from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Cash & Equivalents is $123.0 million, which was down 13.62% from $142.4 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Cash & Equivalents high stood at $166.0 million for Q1 2025, and its period low was $34.2 million during Q2 2024.
  • For the 3-year period, Artiva Biotherapeutics' Cash & Equivalents averaged around $78.3 million, with its median value being $54.8 million (2023).
  • Per our database at Business Quant, Artiva Biotherapeutics' Cash & Equivalents tumbled by 36.22% in 2024 and then soared by 315.79% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Cash & Equivalents stood at $53.5 million in 2023, then dropped by 24.80% to $40.2 million in 2024, then surged by 120.11% to $123.0 million in 2025.
  • Its Cash & Equivalents stands at $123.0 million for Q3 2025, versus $142.4 million for Q2 2025 and $166.0 million for Q1 2025.